1
|
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29]. Ann Oncol 2023; 34:325. [PMID: 36529567 DOI: 10.1016/j.annonc.2022.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- E Zucca
- Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern; Institute of Oncology Research, Bellinzona, Switzerland
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Buske
- Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | - P W Johnson
- Cancer Research UK Centre, Southampton General Hospital, Southampton, UK
| | - M Ponzoni
- Vita-Salute San Raffaele University and Pathology Unit, San Raffaele Scientific Institute, Milan, Italy
| | - M Raderer
- Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
| | - U Ricardi
- Department of Oncology, University of Turin, Turin, Italy
| | - A Salar
- Department of Hematology, Hospital del Mar, Barcelona, Barcelona, Spain
| | - K Stamatopoulos
- Institute of Applied Biosciences, CERTH, the Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - C Thieblemont
- Department of Hematology, APHP-Saint-Louis Hospital, University Paris-Diderot, Paris, France
| | - A Wotherspoon
- Department of Histopathology, The Royal Marsden Hospital, London, UK
| | - M Ladetto
- Division of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | |
Collapse
|
2
|
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7:100403. [PMID: 35272130 PMCID: PMC8795783 DOI: 10.1016/j.esmoop.2022.100403] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 01/13/2022] [Accepted: 01/18/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. METHODS This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND CONCLUSION The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Collapse
Affiliation(s)
- C Buske
- Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
| | - M Dreyling
- Department of Medicine III at LMU Hospital, Munich, Germany
| | - A Alvarez-Larrán
- Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Apperley
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Besson
- Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France
| | - L Bullinger
- Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - P Corradini
- Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - M Giovanni Della Porta
- Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - M Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - S D'Sa
- UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK
| | - H T Eich
- Department of Radiation Oncology, University of Muenster, Münster, Germany
| | - R Foà
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - P Ghia
- Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | - M G da Silva
- Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal
| | - J Gribben
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Hajek
- Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - C Harrison
- Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
| | - B Kiesewetter
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | - J J Kiladjian
- Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France
| | - N Kröger
- Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - P Moreau
- Hematology Department, University Hospital Hotel-Dieu, Nantes, France
| | - J R Passweg
- Hematology Division, Basel University Hospital, Basel, Switzerland
| | - F Peyvandi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - D Rea
- University Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France
| | - J-M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - T Robak
- Department of Hematology, Medical University of Lodz, Lodz, Poland
| | - J F San-Miguel
- Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain
| | - V Santini
- MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy
| | - G Sanz
- Hematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain
| | - P Sonneveld
- Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands
| | - M von Lilienfeld-Toal
- Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany
| | - C Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - F Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
| |
Collapse
|
3
|
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, Orsucci L, Ferreri AJ, Perbellini O, Dodero A, Vallisa D, Pulsoni A, Santoro A, Zuccaro V, Chimienti E, Russo F, Visco C, Zignego AL, Marcheselli L, Luminari S, Paulli M, Bruno R, Arcaini L. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE
FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.77_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Merli
- University Hospital "Ospedale di Circolo e Fondazione Macchi" ‐ ASST Sette Laghi University of Insubria Hematology Varese Italy
| | - S. Rattotti
- Fondazione IRCCS Policlinico San Matteo Hematology Pavia Italy
| | - M. Spina
- Centro di Riferimento Oncologico IRCCS Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - F. Re
- Azienda Ospedaliera Universitaria Hematology and BMT Center Parma Italy
| | - M. Motta
- ASST Spedali Civili Brescia Hematology Brescia Italy
| | - F. Piazza
- Azienda Ospedaliera‐Universitaria University of Padova Medicine, Hematology Padova Italy
| | - L. Orsucci
- Città della Salute e della Scienza di Torino Hematology Torino Italy
| | | | | | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - D. Vallisa
- Ospedale Guglielmo da Saliceto Hematology Piacenza Italy
| | - A. Pulsoni
- Sapienza University of Rome Translational and Precision Medicine Roma Italy
| | - A. Santoro
- Humanitas Research Hospital Medical Oncology and Hematology Unit Rozzano Milan Italy
| | - V. Zuccaro
- Fondazione IRCCS Policlinico San Matteo University of Pavia Infectious and Tropical Diseases Pavia Italy
| | - E. Chimienti
- Centro di Riferimento Oncologico IRCCS Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - F. Russo
- Azienda Ospedaliera Universitaria Hematology and BMT Center Parma Italy
| | - C. Visco
- University of Verona Medicine, Section of Hematology Verona Italy
| | - A. L. Zignego
- University of Florence Clinical and Experimental Medicine Interdepartmental Hepatology Center MASVE Florence Italy
| | | | - S. Luminari
- AUSL ‐ IRCCS Reggio Emilia University of Modena and Reggio Emilia Hematology Reggo Emilia Italy
| | - M. Paulli
- Fondazione IRCCS Policlinico San Matteo University of Pavia Anatomic Pathology Unit Pavia Italy
| | - R. Bruno
- Fondazione IRCCS Policlinico San Matteo University of Pavia Infectious and Tropical Diseases Pavia Italy
| | - L. Arcaini
- University of Pavia Molecular Medicine Pavia Italy
| |
Collapse
|
4
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
5
|
Ferreri AJ, Tarantino V, Cabras G, Ferrara F, Zinzani PL, Arcaini L, Castellino A, Tucci A, Cocito F, Davies A, Salvador Chalup MM, Cwynarski K, Nogueira FL, Petrucci L, Muzi C, Onofrillo D, Ferrario A, Ramakrishnan P, Scalzulli PR, Tani M, Tisi MC, Papageorgiou SG, Calimeri T, Angelillo P, Foppoli M, Dimou M, Ponzoni M, Iannitto E, Vassilakopoulos TP. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT. Hematol Oncol 2021. [DOI: 10.1002/hon.66_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - V. Tarantino
- University of Modena and Reggio Emilia PhD Program in Clinical and Experimental Medicine Modena Italy
| | - G. Cabras
- Ospedale Oncologico Struttura Complessa di Ematologia e CTMO Cagliari Italy
| | - F. Ferrara
- AORN Cardarelli Hospital Division of Hematology and Stem Cell Transplantation Program Naples Italy
| | - P. L. Zinzani
- IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli Bologna Italy
| | - L. Arcaini
- Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine University of Pavia Division of Hematology Pavia Italy
| | | | - A. Tucci
- ASST Spedali Civili Hematology Department Brescia Italy
| | - F. Cocito
- ASST‐Monza UC di Ematologia Monza Italy
| | - A. Davies
- CRUK Centre University of Southampton Faculty of Medicine Southampton Experimental Cancer Medicines Centre Southampton UK
| | - M. M.B Salvador Chalup
- Hematológica Oncoclínicas, Hematological Malignancies and Stem Cell Transplantation Belo Horizonte Brazil
| | - K. Cwynarski
- University College London Hospitals Department of Haematology London UK
| | - F. L. Nogueira
- Gurpo Oncoclínicas Clínica Hematologica Belo Horizonte Minas Gerais Brazil
| | - L. Petrucci
- University Sapienza Hematology Department of Translation and Precision Medicine Rome Italy
| | - C. Muzi
- ASST Grande Ospedale Metropolitano Niguarda Division of Haematology Milan Italy
| | - D. Onofrillo
- Spirito Santo Hospital Pediatric Hematology and Oncology Unit Department of Hematology Pescara Italy
| | | | - P. Ramakrishnan
- Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center Division of Hematologic Malignancies and Cellular Therapy Dallas Texas USA
| | - P. R. Scalzulli
- Fondazione IRCCS “Casa Sollievo della Sofferenza” Division of Hematology San Giovanni Rotondo Italy
| | - M. Tani
- Santa Maria delle Croci Hospital Hematology Unit Ravenna Italy
| | - M. C. Tisi
- San Bortolo Hospital Cell Therapy and Hematology Vicenza Italy
| | - S. G. Papageorgiou
- University General Hospital "Attikon" National and Kapodistrian University of Athens Second Department of Internal Medicine Propaedeutic Hematology Unit Athens Greece
| | - T. Calimeri
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - P. Angelillo
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - M. Foppoli
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - M. Dimou
- General Hospital National and Kapodistrian University of Athens First Department of Internal Medicine, Propaedeutic Haematology Clinical Trial Unit Athens Greece
| | - M. Ponzoni
- Università Vita‐salute San Raffaele Milano, Italy Pathology Unit Milan Italy
| | - E. Iannitto
- Casa di Cura "La Maddalena" Hematology and BMT Department of Oncology Palermo Italy
| | - T. P. Vassilakopoulos
- Laikon General Hospital National and Kapodistrian University of Athens Department of Haematology and Bone Marrow Transplantation Athens Greece
| |
Collapse
|
6
|
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez‐Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Sabattini E, Salles G, Santambrogio E, Scarfó L, Stathis A, Stüssi G, Geyer JT, Tapia G, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, Leval L, Dirnhofer S, Pileri SA, Piris MÁ, Traverse‐Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
7
|
Luminari S, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Zaja F, Marcheselli L, Ferrero S, Arcaini L, Pulsoni A, Musuraca G, Califano C, Merli M, Bari A, Conconi A, Giudice ID, Re F, Stefani PM, Usai SV, Perrone T, Gini G, Falini B, Gattei V, Manni M, Ladetto M, Mannina D, Federico M. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.80_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S. Luminari
- Azienda Unità Sanitaria Locale IRCCS Arcispedale Santa Maria Nuova IRCCS Hematology Unit and University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Reggio Emilia Italy
| | - S. Galimberti
- University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - A. Versari
- Azienda Unità Sanitaria Locale‐IRCCS ‐ Arcispedale Santa Maria Nuova Medicina Nucleare Reggio Emilia Italy
| | - A. Tucci
- ASST Spedali Civili di Brescia SC Ematologia Brescia Italy
| | - C. Boccomini
- A.O.U. Città della Salute e della Scienza di Torino SC Ematologia Torino Italy
| | - L. Farina
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology Milano Italy
| | - F. Zaja
- Università degli Studi di Trieste Dipartimento Clinico di Scienze mediche, chirurgiche e della salute and, Azienda Sanitaria Universitaria Giuliano Isontina SC Ematologia Trieste Italy
| | | | - S. Ferrero
- University of Torino, Hematology Department of Molecular Biotechnologies and Health Sciences and AOU “Città della Salute e della Scienza di Torino” Hematology 1 Torino Italy
| | - L. Arcaini
- Fondazione IRCCS Policlinico San Matteo di Pavia Division of Hematology and University of Pavia Department of Molecular Medicine Pavia Italy
| | - A. Pulsoni
- Sapienza Università di Roma Dipartimento di Biotecnologie Cellulari ed Ematologia Roma Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Department of Hematology Meldola Italy
| | - C. Califano
- Ospedale Umberto I, U.O Medicina‐Oncoematologia Nocera Inferiore Italy
| | - M. Merli
- University Hospital Ospedale di Circolo e Fondazione Macchi ASST Settelaghi Varese Italy
| | - A. Bari
- Università di Modena e Reggio Emilia Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Modena Italy
| | - A. Conconi
- Ospedale degli Infermi Unit of Hematology Biella Italy
| | - I. del Giudice
- Policlinico Umberto I ‐ Università "La Sapienza" ‐ Istituto Ematologia Dipartimento di Medicina Traslazionale e di Precisione Roma Italy
| | - F. Re
- Azienda Ospedaliero Universitaria di Parma UO Ematologia e CTMO Parma Italy
| | - P. M. Stefani
- General Hospital Ca' Foncello Hematology Treviso Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Division of Hematology Cagliari Italy
| | - T. Perrone
- University of Bari Hematology Bari Italy
| | - G. Gini
- Marche Polytechnic University Department of Clinical and Molecular Sciences, Hematology Ancona Italy
| | - B. Falini
- Ospedale S. Maria della Misericordia University of Perugia Institute of Hematology and CREO (Center for Hemato‐Oncological Research) Perugia Italy
| | - V. Gattei
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - M. Manni
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Modena Italy
| | - M. Ladetto
- Università del Piemonte Orientale Dipartimento di Medicina Traslazionale and AO SS Antonio e Biagio e Cesare Arrigo SC Ematologia Alessandria Italy
| | - D. Mannina
- Azienda Ospedaliera Papardo UOC di Ematologia Messina Italy
| | - M. Federico
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Modena Italy
| |
Collapse
|
8
|
Martelli M, Zucca E, Botto B, Kryachok I, Ceriani L, Balzarotti M, Tucci A, Cabras MG, Zilioli VR, Rusconi C, Angrilli F, Arcaini L, Iwanicka AD, Ferreri A, Merli F, Zhao W, Hodgson D, Ionescu C, Fosså A, Cwynarski K, Mikhaeel G, Jerkeman M, Janikova A, Hüttmann A, Ciccone G, Metser U, Barrington S, Malkowski B, Versari A, Esposito F, Cozens K, Ielmini N, Ricardi R, Cavalli F, Johnson P, Davies A. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
9
|
Cereda E, Lobascio F, Crotti S, Masi S, Cappello S, Turri A, Borioli V, Klersy C, Stobäus N, Tank M, Franz K, Cutti S, Arcaini L, Filippi A, Benazzo M, Palladini G, Pedrazzoli P, Norman K, Caccialanza R. The need to reappraise the definition of sarcopenia in cancer patients. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Cereda E, Lobascio F, Masi S, Crotti S, Cappello S, Borioli V, Turri A, Klersy C, Stobäus N, Tank M, Franz K, Cutti S, Giaquinto E, Benazzo M, Filippi A, Arcaini L, Palladini G, Pedrazzoli P, Norman K, Caccialanza R. Importance of body composition in grading body mass index and weight loss-related nutritional risk in cancer patients. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Zappasodi P, Brociner M, Merati G, Nizzoli ME, Roncoroni E, Boveri E, Castagnola C, Arcaini L. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients. Ann Hematol 2020; 100:1111-1113. [PMID: 33175198 DOI: 10.1007/s00277-020-04333-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 10/31/2020] [Indexed: 10/23/2022]
Affiliation(s)
- P Zappasodi
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy.
| | - M Brociner
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - G Merati
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - M E Nizzoli
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - E Roncoroni
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy
| | - E Boveri
- Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - C Castagnola
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy.,Department of Molecular Medicine, University of Pavia, Pavia, Italy
| |
Collapse
|
12
|
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 31:17-29. [PMID: 31912792 DOI: 10.1016/j.annonc.2019.10.010] [Citation(s) in RCA: 150] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/07/2019] [Accepted: 10/09/2019] [Indexed: 02/08/2023] Open
Affiliation(s)
- E Zucca
- Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Buske
- Comprehensive Cancer Centre, University Hospital of Ulm, Ulm, Germany
| | - P W Johnson
- Cancer Research UK Centre, Southampton General Hospital, Southampton, UK
| | - M Ponzoni
- Vita-Salute San Raffaele University and Pathology Unit, San Raffaele Scientific Institute, Milan, Italy
| | - M Raderer
- Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
| | - U Ricardi
- Department of Oncology, University of Turin, Turin, Italy
| | - A Salar
- Department of Hematology, Hospital del Mar, Barcelona, Barcelona, Spain
| | - K Stamatopoulos
- Institute of Applied Biosciences, CERTH, the Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - C Thieblemont
- Department of Hematology, APHP-Saint-Louis Hospital, University Paris-Diderot, Paris, France
| | - A Wotherspoon
- Department of Histopathology, The Royal Marsden Hospital, London, UK
| | - M Ladetto
- Division of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | |
Collapse
|
13
|
Cereda E, Caraccia M, Klersy C, Cappello S, Turri A, Borioli V, Stobäus N, Giannoni A, Arcaini L, Benazzo M, Palladini G, Pedrazzoli P, Norman K, Caccialanza R. SUN-PO217: Validation of a New Prognostic Body Composition Parameter in Cancer Patients. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32849-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, Dondi A, Tucci A, Guerra L, Galimberti S, Cavallo F, Olivieri J, Corradini P, Arcaini L, Chauvie S, Del Giudice I, Rusconi C, Pinto A, Molinari A, Pulsoni A, Merli M, Kovalchuk S, Nassi L, Bolis S, Gattei V, Manni M, Pileri S, Brugiatelli M, Luminari S. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Federico
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - A. Versari
- Nuclear Medicine Unit; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Division of Hematology; University of Torino; Torino Italy
| | - L. Marcheselli
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - C. Boccomini
- SC Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Dondi
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - A. Tucci
- SC Ematologia; ASST-Spedali Civili; Brescia Italy
| | - L. Guerra
- Nuclear Medicine Unit; San Gerardo Hospital; Monza Italy
| | - S. Galimberti
- Division of Hematology, Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - J. Olivieri
- Clinica Ematologica; Centro Trapianti e Terapie Cellulari “C. Melzi”, DAME, ASUI; Udine Italy
| | - P. Corradini
- Department of Oncology and Hematology; Fondazione Istituto Nazionale dei Tumori Milano University of Milano; Milano Italy
| | - L. Arcaini
- Department of Molecular Medicine; University of Pavia, Division of Hematology, Fondazione IRCCS Policlinico S. Matteo; Pavia Italy
| | - S. Chauvie
- Medical Physics Unit; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - I. Del Giudice
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - C. Rusconi
- Division of Hematology; ASST Grande ospedale Metropolitano Niguarda; Milano Italy
| | - A. Pinto
- Department of Hematology and Developmental Therapeutics; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’ IRCCS; Napoli Italy
| | - A. Molinari
- UO Ematologia; OC Rimini AUSL Romagna; Rimini Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - M. Merli
- Hematology; University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria; Varese Italy
| | - S. Kovalchuk
- Ematologia; Università degli Studi di Firenze; Firenze Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - S. Bolis
- Hematolgy Unit; ASST-Monza; Monza Italy
| | - V. Gattei
- Clinical and Experimental Onco-Haematology Unit; Centro di Riferimento Oncologico, IRCCS; Aviano Italy
| | - M. Manni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - S. Pileri
- Divisione di Diagnosi Ematopatologica; Istituto Europeo di Oncologia; Milano Italy
| | - M. Brugiatelli
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - S. Luminari
- S.C. Ematologia; Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia Italy
| |
Collapse
|
15
|
Visco C, Di Rocco A, Tisi M, Morello L, Evangelista A, Zilioli V, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani P, Cox M, Bozzoli V, Fabbri A, Polli V, Ferrero S, De Celis I, Sica A, Arcaini L, Balzarotti M, Rule S, Vitolo U. OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.16_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. Visco
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - A. Di Rocco
- Translational and Precision Medicine; Sapienza University of Rome; Rome Italy
| | - M.C. Tisi
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - L. Morello
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - A. Evangelista
- Clinical Epidemiology; Città della Salute e della Scienza and CPO Piemonte; Torino Italy
| | - V.R. Zilioli
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - C. Rusconi
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - S. Hohaus
- Institute of Hematology, Policlinico Gemelli Foundation; Catholic University of the Sacred Heart; Roma Italy
| | - R. Sciarra
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - A. Re
- Hematology; Spedali Civili; Brescia Italy
| | - C. Tecchio
- Medicine, Section of Hematology and Bone Marrow Transplant; University of Verona; Verona Italy
| | - A. Chiappella
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| | - A. Marin-Niebla
- Hematology; Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Spain
| | - R. McCulloch
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - G. Gini
- Hematology, Department of Clinical and Molecular Sciences; Marche Polytechnic University; Ancona Italy
| | - T. Perrone
- Hematology; University of Bari; Bari Italy
| | - L. Nassi
- Hematology; Azienda Ospedaliero-Universitaria Maggiore della Carità; Novara Italy
| | - E. Pennese
- Hematology; UOSD "Centro Diagnosi e Terapia dei Linfomi"; PO Santo Spirito Pescara Italy
| | - P.M. Stefani
- Hematology; Ca' Foncello Hospital; Treviso Italy
| | - M.C. Cox
- Hematology; AOU Sant'Andrea; Rome Italy
| | | | - A. Fabbri
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - V. Polli
- Hematology; Ospedale degli Infermi; Rimini Italy
| | - S. Ferrero
- Molecular Biotechnologies and Health Sciences; University of Torino/AOU "Città della Salute e della Scienza di Torino"; Torino Italy
| | - I.A. De Celis
- Hematology; AUSLL/IRCCS Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - A. Sica
- Hematology; Policlinico di Napoli; Napoli Italy
| | - L. Arcaini
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Balzarotti
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Rule
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - U. Vitolo
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| |
Collapse
|
16
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
17
|
Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, Canioni D, Michot JM, Visco C, Arcaini L, Besson C, Hermine O. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2019; 29:92-100. [PMID: 29045541 DOI: 10.1093/annonc/mdx635] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL), especially marginal zone lymphoma, de novo or transformed diffuse large B-cell lymphoma and to a lesser extent, follicular lymphoma. Epidemiological data and clinical observations argue for an association between HCV and lymphoproliferative disorders. The causative role of HCV in NHL has been further supported by the response to antiviral therapy. Pathophysiological processes at stake leading from HCV infection to overt lymphoma still need to be further elucidated. Based on reported biological studies, several mechanisms of transformation seem however to emerge. A strong body of evidence supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to frank lymphoma, mostly of marginal zone subtype. By infecting lymphocytes, HCV could play a direct role in cellular transformation, particularly in de novo large B-cell lymphoma. Finally, HCV is associated with follicular lymphoma in a subset of patients. In this setting, it may be hypothesized that inflammatory cytokines stimulate proliferation and transformation of IgH-BCL2 clones that are increased during chronic HCV infection. Unraveling the pathogenesis of HCV-related B-cell lymphoproliferation is of prime importance to optimize therapeutic strategies, especially with the recent development of new direct-acting antiviral drugs.
Collapse
Affiliation(s)
- L Couronné
- Department of Hematology, Assistance Publique-Hôpitaux de Paris (APHP), Necker Hospital, Paris, France.,INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - E Bachy
- Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Lyon, France.,Department of Hematology, Lyon Sud Hospital, Lyon, France
| | - S Roulland
- Center of Immunology of Marseille-Luminy, Aix Marseille University, Marseille, France
| | - B Nadel
- Center of Immunology of Marseille-Luminy, Aix Marseille University, Marseille, France
| | - F Davi
- INSERM U1104, Marseille, France.,CNRS UMR 7280, Marseille, France.,Department of Hematology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France
| | - M Armand
- INSERM U1104, Marseille, France.,CNRS UMR 7280, Marseille, France.,Department of Hematology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France
| | - D Canioni
- Department of Pathology, Necker Hospital, AP-HP, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - J M Michot
- Department of Hematology and Drug Development, Gustave Roussy Institute, Villejuif; France
| | - C Visco
- Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
| | - L Arcaini
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.,Departement of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - C Besson
- Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France.,University of Versailles Saint Quentin en Yvelines, Paris-Saclay University, Communauté Paris-Saclay, Paris, France.,INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, France
| | - O Hermine
- Department of Hematology, Assistance Publique-Hôpitaux de Paris (APHP), Necker Hospital, Paris, France.,INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Paris, France
| |
Collapse
|
18
|
Fedele L, Marchini M, Baglioni A, Arcaini L, Zamberletti D, Carinelli SG. Dental Elements in Mature Teratomas of the Ovary: Scanning Electron Microscope Ultrastructure. Tumori 2018; 75:76-8. [PMID: 2711481 DOI: 10.1177/030089168907500120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Seventy-two teeth from 10 ovarian mature teratomas and 12 unerupted and erupted teeth from subjects aged 8 to 21 years were examined at the scanning electron microscope to evaluate the morphologic and histogenetic differences. The ultrastructure of the teratomatous teeth was similar to that of the corresponding orthotopic tissues. Despite this similarity the morphology of the teratomatous teeth was much less well defined, attesting to the inductive effect of the contiguous tissues that are normally present in the oral cavity.
Collapse
Affiliation(s)
- L Fedele
- 1st Department Obstetrics and Gynecology, University of Milan, Italy
| | | | | | | | | | | |
Collapse
|
19
|
Morello L, Rattotti S, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly T, Di Rocco A, Carli G, Defrancesco I, Giordano L, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Morello
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - S. Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - T. van Meerten
- Department of Hematology; University Medical Center Groningen; Groningen The Netherlands
| | - K. Krawczyk
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - F. Moita
- Instituto Português de Oncologia de Lisboa, Francisco Gentil; Lisbon Portugal
| | - D. Marino
- Oncology Unit 1; Veneto Institute of Oncology IOV-IRCCS; Padova Italy
| | - S. Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences; University of Torino; Torino Italy
| | - M. Szymczyk
- Department of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology; Warsaw Poland
| | - I. Aurer
- Division of Hematology, Department of Internal Medicine; University Hospital Centre Zagreb; Zagreb Croatia
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G. Carli
- Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza Italy
| | - I. Defrancesco
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - L. Giordano
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital Munich; Munchen Germany
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - L. Arcaini
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| |
Collapse
|
20
|
Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres H, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti V, Bruno R, Hermine O, Arcaini L. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Frigeni
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - C. Visco
- Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - C. Besson
- Université Paris Sud, INSERM; Assistance Publique-Hôpitaux de Paris Centre Hospitalier Universitaire Bicêtre; Le Kremlin-Bicêtre France
| | - S. Rattotti
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - H. Fontaine
- Paris 5 Descartes University; INSERM U1213 and Unité Mixte de Service 20; Institut Pasteur, Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Goldaniga
- Department of Hematology, Fondazione Ospedale Maggiore Policlinico; Mangiagalli e Regina Elena; Milan Italy
| | - M. Visentini
- Division of Clinical Immunology; Sapienza University of Rome, Fondazione Roma; Rome Italy
| | - H.A. Torres
- Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center; Houston Texas USA
| | - J. Peveling-Oberhag
- Department of Internal Medicine 1; Goethe-University Hospital; Frankfurt Germany
| | - R. Rossotti
- Department of Infectious Diseases; Ospedale Niguarda Ca’ Granda; Milan Italy
| | - F. Zaja
- Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - L. Rigacci
- Department of Hematology; Azienda Ospedaliero-Universitaria Careggi; Florence Italy
| | - M. Merli
- Division of Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - C. Dorival
- Sorbonne Universités, Pierre and Marie Curie University (University of Paris 06), INSERM; Institut Pierre Louis d'épidémiologie et de Santé Publique (Unité mixte de recherche S1136); Paris France
| | - L. Alric
- Toulouse 3 University, Unité mixte de recherche 152 Institut de Recherche pour le Développement; Department of Internal Medicine and Digestive Diseases, Hôpital Purpan; Toulouse France
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy
| | - M. Gentile
- Hematology Unit; Azienda Ospedaliera di Cosenza; Cosenza Italy
| | - A. Ferrari
- Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - M. Pirisi
- Department of Translational Medicine; Università degli Studi del Piemonte Orientale "A. Avogadro"; Novara Italy
| | - A. Tedeschi
- Department of Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda; Milan Italy
| | - I. Defrancesco
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - V.V. Ferretti
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - R. Bruno
- Division of Infectious and Tropical Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - O. Hermine
- Paris 5 Descartes University; AP-HP, Department of Adult Hematology and Imagine Institute, Hôpital Necker; Paris France
| | - L. Arcaini
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| |
Collapse
|
21
|
Merli M, Alric L, Mannelli L, De Angelis F, Ferrari A, Capecchi M, Pirisi M, Visco C, Piazza F, Loustaud-Ratti V, Goldaniga M, Zancanella M, Cencini E, Marino D, Benanti F, Rumi M, Frigeni M, Gotti M, Sciarra R, Ferretti V, Grossi P, Passamonti F, Bruno R, Arcaini L. DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Merli
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - L. Alric
- Internal Medicine and Digestive Diseases; Toulouse 3 University, Unité mixte de recherche 152, Institut de recherche 152, Institut de Récherche pour le Developpement, Hopital Purpan; Toulouse France
| | - L. Mannelli
- Hematology; Azienda Ospedaliera Careggi; Florence Italy
| | - F. De Angelis
- Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - A. Ferrari
- Hematology; IRCCS Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - M. Capecchi
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - M. Pirisi
- Translational Medicine; University of Piemonte Orientale UPO; Novara Italy
| | - C. Visco
- Cell Therapy and Hematology; Ospedale San Bortolo; Vicenza Italy
| | - F. Piazza
- Medicine-Hematology; University of Padova; Padova Italy
| | - V. Loustaud-Ratti
- Hepatology; Centre Hospitalier Universitaire Limoges, U850 INSERM, Université de Limoges; Limoges France
| | - M. Goldaniga
- Hematology; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Zancanella
- Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda; Milan Italy
| | - E. Cencini
- Hematology, Azienda Ospedaliera Senese; University of Siena; Siena Italy
| | - D. Marino
- Oncology Unit 1, Veneto Institute of Oncology IOV_IRCCS; Padova Italy
| | - F. Benanti
- Infectious Diseases; University of Catania; Catania Italy
| | - M. Rumi
- Hepatology, Ospedale San Giuseppe IRCCS Multimedica; University of Milan; Milan Italy
| | - M. Frigeni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Gotti
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - R. Sciarra
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - V. Ferretti
- Molecular Medicine; University of Pavia; Pavia Italy
| | - P. Grossi
- Infectious and Tropical Diseases; University Hospital Ospedale di Circolo e Fondazione Macchi -ASST Sette Laghi, University of Insubria; Varese Italy
| | - F. Passamonti
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - R. Bruno
- Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo; University of Pavia; Pavia Italy
| | - L. Arcaini
- Molecular Medicine; University of Pavia; Pavia Italy
| |
Collapse
|
22
|
Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 2016; 23:536-44. [PMID: 26924533 DOI: 10.1111/jvh.12518] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2015] [Accepted: 12/15/2015] [Indexed: 12/29/2022]
Abstract
Many epidemiological studies provide solid evidence for an association of chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin's lymphoma (B-NHL). However, the most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication by antiviral therapy (AVT). We conducted a literature search to identify studies that included patients with HCV-associated B-NHL (HCV-NHL) who received AVT, with the intention to treat lymphoma and viral disease at the same time. The primary end point was the correlation of sustained virological response (SVR) under AVT with lymphoma response. Secondary end points were overall lymphoma response rates and HCV-NHL response in correlation with lymphoma subtypes. We included 20 studies that evaluated the efficacy of AVT in HCV-NHL (n = 254 patients). Overall lymphoma response rate through AVT was 73% [95%>confidence interval, (CI) 67-78%]. Throughout studies there was a strong association between SVR and lymphoma response (83% response rate, 95%>CI, 76-88%) compared to a failure in achieving SVR (53% response rate, 95%>CI, 39-67%, P = 0.0002). There was a trend towards favourable response for AVT in HCV-associated marginal zone lymphomas (response rate 81%, 95%>CI, 74-87%) compared to nonmarginal zone origin (response rate 71%, 95%>CI, 61-79%, P = 0.07). In conclusion, in the current meta-analysis, the overall response rate of HCV-NHL under AVT justifies the recommendation for AVT as first-line treatment in patients who do not need immediate conventional treatment. The strong correlation of SVR and lymphoma regression supports the hypothesis of a causal relationship of HCV and lymphomagenesis.
Collapse
Affiliation(s)
- J Peveling-Oberhag
- Department of Internal Medicine 1, Goethe-University Hospital, Frankfurt, Germany
| | - L Arcaini
- Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.,Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - K Bankov
- Department of Internal Medicine 1, Goethe-University Hospital, Frankfurt, Germany
| | - S Zeuzem
- Department of Internal Medicine 1, Goethe-University Hospital, Frankfurt, Germany
| | - E Herrmann
- Institute for Biostatistics and Mathematical Modelling, Goethe-University, Frankfurt, Germany
| |
Collapse
|
23
|
Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia 2014; 29:503-7. [DOI: 10.1038/leu.2014.294] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
24
|
Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014; 25:1404-1410. [PMID: 24799461 DOI: 10.1093/annonc/mdu166] [Citation(s) in RCA: 117] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). PATIENTS AND METHODS We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. RESULTS For entire cohort, 5-year overall survival (OS) was 78% [95% confidence interval (CI): 74%-82%] and 5-year progression-free survival (PFS) was 48% (95% CI: 44%-53%). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%-73%). CR + PR rate was 85% with AT as second-line treatment. CONCLUSION AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related indolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for patients with indolent lymphomas who do not need immediate cytoreductive treatment.
Collapse
Affiliation(s)
- L Arcaini
- Department of Molecular Medicine, University of Pavia, Pavia; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia.
| | - D Vallisa
- Division of Hematology, Ospedale Giovanni da Saliceto, Piacenza
| | - S Rattotti
- Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia
| | - V V Ferretti
- Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia
| | - A J M Ferreri
- Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milano
| | - P Bernuzzi
- Division of Hematology, Ospedale Giovanni da Saliceto, Piacenza
| | - M Merli
- Division of Hematology, Department of Internal Medicine, Ospedale di Circolo, Fondazione Macchi, Varese
| | - M Varettoni
- Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia
| | - A Chiappella
- Division of Hematology 2, AO S Giovanni Battista, Torino
| | - A Ambrosetti
- Department of Medicine, Section of Hematology, University of Verona, Verona
| | - A Tucci
- Division of Hematology, Spedali Civili, Brescia
| | - C Rusconi
- Division of Hematology, Ospedale Niguarda Ca' Granda, Milano
| | - C Visco
- Division of Hematology, Ospedale San Bortolo, Vicenza
| | - M Spina
- Division of Medical Oncology, National Cancer Center, Aviano
| | - G Cabras
- Division of Hematology, Osp A Businco, Cagliari
| | - S Luminari
- Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena
| | - M Tucci
- IMO, Department of Internal Medicine and Clinical Oncology, University of Bari, Aldo Moro, Bari
| | - P Musto
- Scientific Direction, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture
| | - M Ladetto
- Division of Hematology, Department of Experimental Medicine and Oncology, University of Torino, Torino
| | - F Merli
- Hematology Unit, Department of Oncology, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia
| | - C Stelitano
- Division of Hematology, Dipartimento di Ematologia, Ospedale M. Morelli, Reggio Calabria
| | - A d'Arco
- Division of Oncohematology, Ospedale Umberto I, Nocera Inferiore
| | - L Rigacci
- Division of Hematology, Azienda Ospedaliero Universitaria Careggi, Firenze
| | - A Levis
- Division of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria
| | - D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - P Spedini
- Division of Haematology, Hospital of Cremona, Cremona
| | - S Mancuso
- Division of Hematology, Policlinico, Palermo
| | - D Marino
- Department of Oncology, Istituto Oncologico Veneto, IRCCS, Padova
| | - R Bruno
- Division of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Clinical Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia
| | - L Baldini
- Division of Hematology, Fondazione IRCCS Cà Granda OM Policlinico, Università degli Studi, Milano
| | - A Pulsoni
- Division of Hematology, Sapienza University, Rome, Italy
| |
Collapse
|
25
|
Cheah C, George A, Giné E, Chiappella A, Kluin-Nelemans H, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer R, Ritchie D, Arcaini L, Williams M, Dreyling M, Seymour J. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24:2119-23. [DOI: 10.1093/annonc/mdt139] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, Spina M, Ferreri A, Zinzani P, Gallamini A, Mastronardi S, Boccomini C, Gaidano G, D'Arco A, Di Raimondo F, Carella A, Santoro A, Musto P, Federico M. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013; 24:2108-12. [DOI: 10.1093/annonc/mdt137] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
27
|
Fiandrino G, Arra M, Riboni R, Lucioni M, Dallera E, Arcaini L, Berti E, Paulli M. Absence ofMYD88L265P mutation in blastic plasmacytoid dendritic cell neoplasm. Br J Dermatol 2013; 168:883-4. [DOI: 10.1111/bjd.12061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24:857-77. [PMID: 23425945 DOI: 10.1093/annonc/mds643] [Citation(s) in RCA: 223] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma. The conference convened ∼30 experts from all around Europe, and selected six lymphoma entities to be addressed; for each of them, three to five open questions were to be addressed by the experts. For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.
Collapse
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital, LMU Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Lombardo GA, Rupoli S, Alaibac M, Arcaini L, Bagnato S, Baldo A, Bottoni U, Carbone A, Cestari R Clerico R, De Renzo A, Fava P, Fierro MT, Filotico R, Fimiani M, Frontani M Girgenti V, Goteri G, Leali C, Mamusa AM, Mariotti G, Mastrandrea V, Pellegrini C, Pennese E, Pileri A, Savoia P, Stelitano C, Titli S, Virgili A, Zichichi L, Zinzani PL, Bernengo MG. Mycosis fungoides: disease evolution of the "lion queen" revisited. GIORN ITAL DERMAT V 2012; 147:523-531. [PMID: 23149698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Mycosis fungoides (MF), which represents the most common subtype of primary cutaneous T-cell lymphoma (CTCL), is an epidermotropic lymphoma included as an indolent form in the recent WHO/EORTC classification. From a clinical point of view, the classic disease progression usually is slow and takes over years or even decades, and characterized by the evolution from patches to more infiltrated plaques and eventually to tumours or erythroderma. However, the analysis of the MF disease course has been greatly impaired by the rarity of the disease, thus data about the time course of disease progression and pattern of relapse during time are not well known. In this review, a summary of published data on MF large patients cohorts will be presented, together with the results obtained by a retrospective analysis of clinical features and follow-up data of 1,422 MF patients diagnosed and followed-up from 1975 to 2010 in 27 Italian Centres (Italian Study Group for Cutaneous Lymphoma). From a clinical perspective, the amount of data support the relevance of a stage-tailored, differentiated follow-up strategy, in as much as the TNMB staging appears not only to be associated with different progression rates, but also shows as a new finding a relationship with different patterns of disease progression. From a biological point of view, there is the need to understand the molecular basis of the different clinical pathways of disease progression, to be able to potentially identify at an earlier phase of disease evolution, the patients who are more likely to develop erythroderma or tumour-stage progression. In conclusion, if MF is indeed a true "lion queen", as dermatologists we need to be expert and wise tamers to keep it under control.
Collapse
Affiliation(s)
- P Quaglino
- Department of Biomedical Sciences and Human Oncology, Dermatologic Clinic, University of Turin, Turin, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Varettoni M, Tedeschi A, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E. Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol 2012; 23:411-5. [DOI: 10.1093/annonc/mdr119] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
31
|
Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24:1574-9. [PMID: 20631743 DOI: 10.1038/leu.2010.148] [Citation(s) in RCA: 271] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia vera (PV). The percentage of granulocyte mutant alleles was evaluated using a quantitative real-time polymerase chain reaction-based allelic discrimination assay. Of the 338 patients enrolled in this prospective study, 320 (94.7%) carried the JAK2 (V617F) mutation. Direct relationships were found between mutant allele burden and hemoglobin concentration (P=0.001), white blood cell count (P=0.001), spleen size (P=0.001) and age-adjusted bone marrow cellularity (P=0.002), while an inverse relationship was found with platelet count (P<0.001). During the study period, eight patients progressed to post-PV myelofibrosis (MF) (all carrying >50% mutant alleles), while 10 patients developed acute myeloid leukemia (AML). The mutant allele burden was significantly related to the risk of developing myelofibrosis (P=0.029) and retained its significant effect also in multivariable analysis (P=0.03). By contrast, the risk of developing AML as well as that of thrombosis was not significantly related to mutant allele burden. Leukocytosis did not affect thrombosis, MF, leukemia or survival. In conclusion, a JAK2 (V617F) allele burden >50% represents a risk factor for progression to MF in PV.
Collapse
Affiliation(s)
- F Passamonti
- Division of Hematology, Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Noris P, Klersy C, Zecca M, Arcaini L, Pecci A, Melazzini F, Terulla V, Bozzi V, Ambaglio C, Passamonti F, Locatelli F, Balduini CL. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7:2131-6. [PMID: 19740094 DOI: 10.1111/j.1538-7836.2009.03614.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Distinguishing inherited thrombocytopenias from immune thrombocytopenia (ITP) can be difficult, and patients are therefore at risk of misdiagnosis and inappropriate treatments. Although it is known that the most common inherited forms of thrombocytopenia are characterized by increased platelet size, the diagnostic power of this feature has never been investigated. OBJECTIVES The aim of this study was to test the hypothesis that platelet size can be used to differentiate ITP from inherited macrothrombocytopenias. PATIENTS/METHODS We measured mean platelet volume (MPV) and mean platelet diameter (MPD), within 2 h of blood sampling, in 35 patients with inherited macrothrombocytopenias [15 MYH9-related disease (MYH9-RD), three biallelic and 17 monoallelic Bernard-Soulier syndrome (BSS)], and 56 with ITP. Using receiving operating characteristic analysis, we searched for the best cut-off values to differentiate between these conditions. RESULTS As expected, platelets were larger in inherited macrothrombocytopenias than in ITP. An MPD larger than 3.3 mum differentiated MYH9-RD and BSS from ITP with 0.89 sensitivity and 0.88 specificity, and an MPV larger than 12.4 fL had 0.83 sensitivity and 0.89 specificity. Combining MPD with MPV increased sensitivity and specificity to 0.97 and 0.89, respectively. CONCLUSION Platelet size evaluation by both an appropriate cell counter and blood film examination is useful for differentiating inherited macrothrombocytopenias from ITP.
Collapse
Affiliation(s)
- P Noris
- Department of Internal Medicine, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, Merli M, Rattotti S, Rossi D, Riboni R, Berti E, Magrini U, Bruno R, Gaidano G, Lazzarino M. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol 2009; 21:1189-1195. [PMID: 19858084 DOI: 10.1093/annonc/mdp454] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) infection has been linked to lymphoproliferative disorders. Marginal zone B-cell lymphoma (MZL) represents one of the most frequent lymphoma subtypes associated with HCV infection. We describe an unusual subset of HCV-associated MZL characterized by subcutaneous presentation. MATERIALS AND METHODS A series of 12 HCV-positive patients presenting with subcutaneous nodules that revealed lymphoma infiltration at biopsy. Molecular analysis of immunoglobulin heavy chain (IGH) gene rearrangement and FISH investigations for t(11;18)(q21;q21) and t(14;18)(q32;q21) were carried out in nine patients. RESULTS The 12 patients (median age 69.5 years), all with positive HCV serology, presented with single or multiple subcutaneous nodules resembling lipomas. Histologically the lesions showed lymphoid infiltrates, consistent with extranodal MZL of mucosa-associated lymphoid tissue (MALT). Functional IGH gene rearrangements were identified in nine tested patients, with somatic mutations in 82%, indicating a histogenesis from germinal center-experienced B cells. The t(11;18) was found in two of nine cases. Staging did not show any other lymphoma localization. In two patients, a response was achieved with antiviral treatment. Extracutaneous spread to MALT sites occurred in a case. CONCLUSIONS Our observations expand the spectrum of HCV-associated lymphomas to include a subset of extranodal MZL characterized by a novel primary 'lipoma-like' subcutaneous presentation and indolent clinical course.
Collapse
Affiliation(s)
- M Paulli
- Pathology Section, Department of Human Pathology.
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - M Lucioni
- Pathology Section, Department of Human Pathology
| | - E Boveri
- Pathology Section, Department of Human Pathology
| | - D Capello
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - F Passamonti
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - M Merli
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - S Rattotti
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - D Rossi
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - R Riboni
- Pathology Section, Department of Human Pathology
| | - E Berti
- Department of Dermatology, University of Milano-Bicocca, Milano
| | - U Magrini
- Pathology Section, Department of Human Pathology
| | - R Bruno
- Division of Tropical and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - G Gaidano
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - M Lazzarino
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| |
Collapse
|
34
|
Federici D, Conti E, Muggiasca ML, Ferrari S, Arcaini L, Brambilla T, Meroni M, Agarossi A. Laparoscopic conservative surgery in tubal pregnancy. MINIM INVASIV THER 2009. [DOI: 10.3109/13645709409152730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
35
|
Arcaini L, Federici D, Muggiasca L, Ghetti E, Conti M. Hysteroscopic metroplasty. MINIM INVASIV THER 2009. [DOI: 10.3109/13645709509152785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
36
|
Federici D, Brambilla T, Lacelli B, Arcaini L, Motta G, Agarossi A, Muggiasca L, Conti M. Pain relief after combined medical and laparoscopic conservative treatment of stage III–IV endometriosis: A comparison with medical therapy. MINIM INVASIV THER 2009. [DOI: 10.3109/13645709609152702] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
37
|
|
38
|
Rumi E, Passamonti F, Pagano L, Ammirabile M, Arcaini L, Elena C, Flagiello A, Tedesco R, Vercellati C, Marcello AP, Pietra D, Moratti R, Cazzola M, Lazzarino M. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. J Intern Med 2009; 265:266-74. [PMID: 18793248 DOI: 10.1111/j.1365-2796.2008.02014.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND High oxygen-affinity haemoglobin variants and 2,3-diphosphoglycerate (2,3-DPG) deficiency are inherited diseases generating low tissue oxygen tension and erythropoietin-driven erythrocytosis, that characterizes the clinical phenotype of patients. Level of blood p50 (the oxygen tension at which haemoglobin is 50% saturated) is used to recognize these conditions. OBJECTIVES To define the clinical utility of blood p50 measurement in the diagnosis of isolated erythrocytosis. SUBJECTS AND DESIGN Venous blood p50 measurement was included in the diagnostic work-up of 102 consecutive patients with isolated erythrocytosis besides blood cell count, arterial oxygen saturation, serum erythropoietin measurement and screening for JAK2 mutations. SETTING Haematological Outpatient Section at University Hospital. RESULTS Seven patients had relative erythrocytosis. Among 95 patients with absolute erythrocytosis, 4 (4.2%) had decreased p50 level. The extended study of family members revealed a familial inheritance. Two families had haemoglobin variants already described as Haemoglobin Malmö and Haemoglobin San Diego. In one family, the proband had a new high oxygen-affinity haemoglobin variant (Haemoglobin Safi) resulting from the transversion C-->A at codon 81 of the alpha2-globin gene. In the last family, a deficiency of 2,3-DPG was found. Within the 91 patients with normal p50 values, 46 (51%) had secondary erythrocytosis, 13 (14%) polycythemia vera and 32 (35%) idiopathic erythrocytosis. CONCLUSIONS This study suggests that the investigation of blood p50 level may be useful to define diagnosis in patients with isolated erythrocytosis.
Collapse
Affiliation(s)
- E Rumi
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, Rumi E, Rattotti S, Lucioni M, Picone C, Castello A, Pascutto C, Magrini U, Lazzarino M, Paulli M. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol 2009; 20:129-36. [DOI: 10.1093/annonc/mdn563] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Wenger MK, Foa R, Arcaini L, Vranovský A, Ivanova V, Van Hazel GA, Kurtovic S, Durán S, Gamba E, Thurley D. Safety in patients receiving maintenance rituximab for follicular lymphoma: Results from the phase IIIb MAXIMA trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008; 19:1331-1335. [PMID: 18344536 DOI: 10.1093/annonc/mdn044] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND To evaluate the clinical outcome of patients with relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and high-dose therapy with autotransplant. PATIENTS AND METHODS Sixty-four patients were enrolled in the trial. Primary end point was progression-free survival (PFS). Secondary end points were the in vivo purging effect on stem-cell harvest and the impact of molecular response on the outcome. RESULTS At enrollment, 59% of patients were PCR+ for bcl-2 rearrangement in bone marrow (PCR-informative). After the immunochemotherapy, before mobilization, 97% obtained complete response or partial response and 87% of patients informative for bcl-2 were molecularly negative. Sixty-one patients proceeded to in vivo purging and peripheral blood stem cell (PBSC) mobilization with rituximab and high-dose AraC. The median number of CD34+ cells collected was 16.6 x 10(6)/kg. Of 33 PCR-informative patients, the harvests resulted in PCR- in all. Fifty-eight patients received high-dose therapy and autotransplant of in vivo purged PBSC. After a median follow-up of 3.5 years, 41 patients are in complete remission. Five-year PFS is 59%. CONCLUSION This study demonstrates that patients with advanced relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and autotransplant may obtain long-lasting PFS. In bcl-2-positive patients, in vivo purging allows the harvest of lymphoma-free PBSC. Absence of the bcl-2 rearrangement after autotransplant is associated with persistent clinical remission.
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia.
| | - F Montanari
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - E P Alessandrino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - A Tucci
- Division of Hematology, Ospedali Civili, Brescia
| | - E Brusamolino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - L Gargantini
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - R Cairoli
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - P Bernasconi
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - F Passamonti
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - M Bonfichi
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - V Zoli
- Division of Hematology, Ospedale S. Camillo, Roma, Italy
| | - C Bottelli
- Division of Hematology, Ospedali Civili, Brescia
| | - S Calatroni
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - D Troletti
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - M Merli
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - C Pascutto
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - I Majolino
- Division of Hematology, Ospedale S. Camillo, Roma, Italy
| | - G Rossi
- Division of Hematology, Ospedali Civili, Brescia
| | - E Morra
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - M Lazzarino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| |
Collapse
|
42
|
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2006; 18:346-50. [PMID: 17071937 DOI: 10.1093/annonc/mdl388] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. METHODS We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. RESULTS HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. CONCLUSIONS This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006; 17:1434-40. [PMID: 16766591 DOI: 10.1093/annonc/mdl131] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) has been correlated to hepatitis C virus (HCV) infection in few series, but characteristics and outcome of these patients remain undefined. PATIENTS AND METHODS We analyzed 156 previously untreated consecutive HCV-positive patients with DLBCL observed between 1994 and 2004 in three major institutions from northern Italy. RESULTS Median age at presentation was 63 years and 8% of patients had DLBCL transformed from low-grade lymphomas. Spleen was the most frequently involved extranodal site, followed by liver and stomach. Treatment was delivered with cure-intent in 132 patients, while the remaining 24 patients received monochemotherapy or radiotherapy alone due to old age or seriously impaired hepatic function. Only five patients (4%) had to discontinue chemotherapy due to severe liver function impairment. The addition of rituximab did not seem to affect patients' tolerance to treatment. Five-year overall survival of the entire cohort was 72%, while 5-year progression-free survival (PFS) of the 132 patients treated with cure-intent was 51%. Hepatitis B virus co-infection, advanced Ann Arbor stage and nodal origin of the tumor resulted the strongest adverse prognostic factors. CONCLUSIONS Patients with HCV-positive DLBCL share distinctive clinical features. Future studies should prospectively evaluate the association between HCV and aggressive lymphomas.
Collapse
Affiliation(s)
- C Visco
- Department of Hematology, Ospedale S. Bortolo, Vicenza, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Passamonti F, Pietra D, Rumi E, Arcaini L, Della Porta MG, Malcovati L, Pascutto C, Lazzarino M, Cazzola M. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. Leukemia 2005; 19:888-9. [PMID: 15744342 DOI: 10.1038/sj.leu.2403700] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
45
|
McCloskey SM, McMullin MF, Morris TCM, Markey GM, Izraeli S, O‘Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM, Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, Arcaini L, Pasini F, Biasi D, Orlandi E, D'Adda M, Lucioni M, Pizzolo G, Mitsui T, Maekawa I, Yamane A, Ishikawa T, Koiso H, Yokohama A, Handa H, Matsushima T, Tsukamoto N, Murakami H, Nojima Y, Karasawa M, Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TRJ, Shaughnessy J, Henschler R, Fehervizyova Z, Bistrian R, Seifried E, Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DBL, Murphy MF, Strawn WB, Richmond RS, Tallant EA, Gallagher PE, Ferrario CM. Papers to be published in forthcoming issues. Bone marrow architecture in acute myeloid/erythroid leukaemia. Leukemia - a developmental perspective. Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant. Most cases of primary. Br J Haematol 2004. [DOI: 10.1111/j.1365-2141.2004.v125_i6_forth.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34:175-9. [PMID: 15170171 DOI: 10.1038/sj.bmt.1704551] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking immunochemotherapy with Rituximab, Vincristine and Cyclophosphamide, we used a combination of Rituximab, HD cytarabine and granulocyte colony-stimulating factor for peripheral blood stem cells (PBSC) mobilization. The median number of CD34+ cells collected was 14.69 x 10(6)/kg (range 5.74-73.2). Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood. B-cell depletion persists during mobilization with Rituximab and HD cytarabine allowing a collection of PBSC free of B cells (median CD19+ and CD20+ cells counts 0%). Of nine patients PCR positive for bcl-2 or bcl-1 in blood and marrow at the start of immunochemotherapy, all showed PCR-negative PBSC. In conclusion, in patients with indolent lymphoma, the concurrent administration of Rituximab and HD cytarabine is a safe and efficient method to obtain in vivo purged PBSC. Immunochemotherapy prior to mobilization produces B-cell depletion and seems to be a useful preparative step.
Collapse
MESH Headings
- Adult
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD34/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- B-Lymphocytes/drug effects
- B-Lymphocytes/immunology
- Bone Marrow Purging/methods
- Cytarabine/therapeutic use
- Female
- Hematopoietic Stem Cell Mobilization/methods
- Humans
- Immunophenotyping
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/therapy
- Lymphoma, Mantle-Cell/drug therapy
- Lymphoma, Mantle-Cell/therapy
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation/methods
- Rituximab
- Salvage Therapy/methods
- Transplantation, Autologous
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116:229-35. [PMID: 11841421 DOI: 10.1046/j.1365-2141.2002.03256.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Options for relapsed/refractory indolent lymphoma include chemotherapy, immunotherapy and high-dose therapy with autologous support. The best combination of these approaches, however, is not defined. We treated 10 patients with relapsed/refractory follicular (n = 7) or mantle cell lymphoma (n = 3) using chemotherapy, immunotherapy, high-dose therapy and autotransplant in a sequence of four phases, each designed to play a specific role in tumour eradication. After the debulking with VACOP-B (doxorubicin, cyclophosphamide, etoposide, vincristine, prednisone, bleomycin) (phase 1), 9/10 patients responded but none achieved a molecular response. After the immuno-chemotherapy phase, which combined Rituximab with vincristine and cyclophosphamide, seven patients were in complete response (CR) and three in good partial response (PR), and all those with a molecular marker of disease showed a disappearance of the signal from marrow and blood. Phase 3, which coupled high-dose cytarabine with Rituximab, was effective in mobilizing an adequate number of progenitor cells that were polymerase chain reaction negative in all informative cases. Phase 4 consisted of high-dose therapy with autologous support followed by two doses of Rituximab. Autograft was performed in nine patients. The haematopoietic recovery was as expected. This sequence of chemotherapy, immuno-chemotherapy, stem cell mobilization with in vivo purging and autotransplant, organized in four blocks of treatment, was simple to administer and devoid of toxic effects. It permits rapid attainment of clinical and molecular response and enables the harvest of lymphoma-free peripheral blood progenitor cells even in heavily pretreated patients with relapsed or refractory disease.
Collapse
Affiliation(s)
- M Lazzarino
- Division of Hematology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Arcaini L, Cerani P, Lorenzi A, Lazzarino M. A young woman with microcytic anemia and hypertransaminasemia. Haematologica 2001; 86:E24. [PMID: 11602431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
|
49
|
Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001; 86:394-8. [PMID: 11325645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Skeletal involvement is typical of multiple myeloma (MM) and its occurrence increases with the progression of the disease. We performed a study to evaluate the clinical importance of osteocalcin (bone gla-protein, BGP) and bone alkaline phosphatase (b-AP) as indices of osteoblastic activity, and deoxypyridoline (DPD) as a marker of bone resorption. DESIGN AND METHODS Fifty-two MM patients, 39 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 normal controls entered the study. Of the 52 MM patients, 10 showed lytic lesions at standard X-rays and 42 did not; 21 were untreated and 31 had been treated with chemotherapy (combined with bisphophonates in 15). Of these last, 12 had progressive disease and 19 were in plateau phase. RESULTS DPD levels were higher in MM patients than in patients with MGUS or healthy controls (p = 0.0001 and p = 0.0008, respectively). No statistical differences were seen between patients with MGUS and healthy controls. BGP serum levels were significantly lower in MM patients than in MGUS patients (p = 0.001) or healthy controls (p = 0.001). b-AP was significantly higher in MGUS patients than in MM patients (p = 0.04). Biochemical parameters were analyzed in a continuous fashion and after dichotomization into low and high values with respect to normal ones. Abnormal high values of DPD showed statistically significant correlations with presence of osteolysis (p = 0.008), advanced stage (p = 0.03) and abnormal beta2-microglobulin (beta2M) values (p = 0.03), while DPD as a continuous variable correlated significantly only with the presence of osteolysis (p = 0.02). In contrast, neither BGP nor b-AP showed statistical correlations with the presence of lytic lesions, or with other clinical or laboratory parameters. In 15 patients followed with serial controls, modifications of DPD levels reflected bone disease status well. Of the 42 patients without radiologic evidence of skeletal lesions, 15 had abnormal DPD values. Spinal magnetic resonance imaging (MRI) showed initial lytic lesions in 10 of them. INTERPRETATION AND CONCLUSIONS Biochemical markers of bone metabolism are useful in evaluating and monitoring skeletal involvement in MM patients. They may help clinicians to identify: 1) from among patients without radiologic evidence of lytic lesions, those who deserve more accurate radiologic examinations (namely MRI); 2) from among asymptomatic patients, and in association with spinal MRI, those patients at higher risk of progression who might benefit from early treatment.
Collapse
Affiliation(s)
- A Corso
- Institute of Hematology, University of Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Schneider A, Greene RE, Keyl C, Bandinelli G, Passino C, Spadacini G, Bonfichi M, Arcaini L, Malcovati L, Boiardi A, Feil P, Bernardi L. Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives. J Hypertens 2001; 19:213-22. [PMID: 11212963 DOI: 10.1097/00004872-200102000-00007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVES Regulation of the vascular system may limit physical performance and contribute to adaptation to high altitude. We evaluated vascular function in 10 Himalayan high-altitude natives and 10 recently acclimatized sea-level natives at an altitude of 5,050 m. METHODS We registered electrocardiogram, blood flow velocity in the common femoral artery, and blood pressure in the radial artery using non-invasive methods under baseline conditions, and during maximal vasodilation after 2 min leg occlusion. Vascular mechanics were characterized by estimating pulse wave velocity and input impedance. RESULTS Pulse wave velocity and parameters of input impedance did not differ between groups under baseline conditions. In the post-ischemic period, the ratio between maximal hyperemic and baseline blood flow velocity was significantly higher in the high-altitude than in the sea-level natives (5.7 +/- 2.5 versus 3.8 +/- 1.2, P < 0.05). The leg vascular resistance decreased in the post-occlusive period without differences between groups. Characteristic impedance decreased in the post-ischemic period by about one third of the baseline level without differences between groups. The post-ischemic decrease of input impedance modulus was more marked in the high-altitude than in the sea-level natives at low frequencies (28 +/- 12 versus 6.4 +/- 20% at 2 Hz, P < 0.01). CONCLUSIONS Our results demonstrate a superior ability to increase blood flow velocity as a response to muscular ischemia in high-altitude natives compared to sea-level natives. This phenomenon may be associated with a more effective coupling between blood pressure and blood flow which is probably caused by differences in conduit vessel function.
Collapse
Affiliation(s)
- A Schneider
- Department of Anesthesiology, University Medical Centre Regensburg, University of Regensburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|